







EDITCEME **EDITGENE** piggyBac Transposon System Reagent

Product Manual





CONTENTS

TOEIN'	HO.
Product Information	3
Product Overview	3
Application Scope	4
Product Components	4
Kit Components	4
Plasmid Map Diagram	4
Storage Conditions and Shelf Life	5
Additional Required Materials	5
 Workflow Diagram 	5
Experimental Procedures	6
Cell Pre-Experiment	6
Main Experiment	6
► FAQs and Solutions	8
Application Example	9
► Notes	10
Appendix	11

piggyBac Transposon System Kit



Product Overview

This kit is a piggyBac Transposon System Kit, providing cells and PB system plasmids. The PB system plasmids include:

- Helper Plasmid: Encodes the transposase enzyme.
- **Transposon Plasmid**: Contains inverted terminal repeats (ITRs) specific to the transposon at both ends, with the transposable gene region in the middle, which can integrate into the host genome.

In the experiment, both the helper plasmid and transposon plasmid are co-transfected into target cells. The transposase encoded by the helper plasmid recognizes the ITR sequences at both ends of the transposon plasmid, cuts them, and integrates the transposable gene region into TTAA sites in the host genome, generating TTAA repeats at both ends of the transposed region. When the helper plasmid is re-transfected, the transposase can remove the transposon from the genome.

As a non-viral vector, the piggyBac transposon system offers several advantages over traditional viral vectors: it has high safety, is easy to use (allowing direct plasmid transfection into cells), supports large vector capacity for co-expression of multiple genes, allows adjustment of helper and transposon plasmid ratios to improve integration efficiency of exogenous genes, enables precise determination of gene insertion sites by inverse PCR, achieves precise excision of the transposon upon re-transposition, has a broad host range, high transposition efficiency, and minimal reliance on host factors.

Application Scope

This kit is a non-viral gene delivery tool, suitable for applications including but not limited to gene therapy, somatic cell reprogramming, cell and animal model construction, and gene-edited cell line development.

Product Components

• Kit Components

	Component		Specification	Storage Temperature	
PB System	Helper Plasmid (500 ng/µL)	pCAG-PBase	4 µg	-20°C	
Plasmids	Transposon Plasmid (500 ng/µL)	PB-CMV-MCS-EFI α-CopGFP-T2A-Pu ro	10 µg	-20°C	
Cells (optional)			1×10 ⁶ /tube	Liquid nitrogen	

• Plasmid Map Diagram



Note:

1. To facilitate enrichment of successfully transposed cells post-transfection, PB Plasmids have puromycin resistance. Additionally, PB-CopGFP also has puromycin resistance, which can be used for pre-transfection and selection.

2. This kit is suitable for five transfections in a 6-well plate. The recommended transfection mass ratio of helper plasmid to transposon plasmid is adjustable from 1:2.5 to 1:5, with an optimal ratio of 1:3.

3. It is recommended to use this kit in combination with cells provided by EDITGENE for best results.

Storage Conditions and Shelf Life

Storage: -20 °C, shelf life of 1 year

Additional Required Materials

To complete this experiment, other materials not provided in this kit may be required:



Figure 1. Schematic Diagram of PB Gene Transposed Cell Line Construction Workflow

Experimental Procedures

Cell Pre-Experiment

1. Transfection Pre-Experiment

The transposon plasmid in the kit contains green fluorescent CopGFP, which can be used with the helper plasmid or individually for transient transfection. It is suitable for optimizing transfection conditions to facilitate the main experiment.

Note: Efficient transfection is essential for successful editing. Common cell lines like 293T, HeLa, A549, and N2A are effectively transfected with lipofection. For therapeutically relevant cells, transfection may be challenging and may require different methods and parameters. It is advisable to optimize the transfection method before the experiment.

2. Determining Puromycin Selection Concentration

(1) Seed cells in the logarithmic growth phase into a 12-well plate with 1 mL of medium per well and incubate for 24 hours.

(2) When cells reach 60%-70% confluency, replace the medium with selection medium containing different concentrations of puromycin (e.g., 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5 μ g/mL).

(3) Replace with fresh puromycin-containing medium every 2 days. After 7 days, observe under a microscope and select the minimum concentration that completely kills the cells for use in future experiments (optimal selection concentration).

Main Experiment

1. Cell Transfection

Using Lipofectamine 3000 (Lipo 3000) as an example, if electroporation is used, optimize conditions based on the electroporator's recommended parameters.

(1) Digest and count cells in the logarithmic growth phase.

(2) Seed an appropriate number of cells into a 6-well plate and incubate.

Note: Due to different growth rates, ensure approximately 80% confluency after 18-24 hours.

- (3) After 18-24 hours, transfect cells when they reach 80% confluency.
- (4) Prepare the plasmid mixture as shown in the table below:

Component	Amount for 6-well plate
Helper Plasmid	0.6 µg
Transposon Plasmid	1.9 µg
Add opti-MEM I to	125 μL

- (5) Add 2 µL of P3000 reagent, gently mix.
- (6) Prepare Lipo 3000-Opti-MEM I mixture and gently mix:

Component	Amount for 6-well plate
Lipo 3000	7.5 μL
Add opti-MEM I to	125 μL

- (7) Add 125 μL of plasmid mixture to 125 μL of Lipo 3000-Opti-MEM I mixture, gently mix, incubate at room temperature for 15 minutes, then carefully add to the medium and gently shake. Incubate the plate.
- (8) The next morning, transfer cells to a T25 flask and continue incubation. Note: Lipofectamine 3000 can be cytotoxic; it is recommended to change the medium 4-24 hours post-transfection.

2. Antibiotic Selection

48 hours post-transfection, observe cell viability and fluorescence under a microscope, then replace with puromycin-containing medium for selection. Use the optimal concentration determined in the pre-experiment. Continue selection for 2 weeks, then switch to medium with half the concentration of puromycin for expansion.

3. Detection of Gene Transposed Cell Lines

After selection, the successfully transposed cells can be analyzed for gene expression levels using qPCR or Western Blot (WB).

4. Cell Expansion and Cryopreservation

Expand and cryopreserve validated cells with half-dose puromycin maintenance, or

proceed with downstream experiments.

FAQs and Solutions

1. Does the piggyBac Transposon System Kit recommend lipofection or electroporation?

A: The PB system in this kit includes plasmids compatible with lipofection, electroporation, or other transfection methods. You can select the transfection method and parameters based on cell type. Most adherent cells are compatible with various transfection methods, while electroporation is recommended for therapeutically relevant cells.

2. What should I do if the transfection efficiency in target cells is low?

A: Before the main experiment, conduct a transfection pre-experiment to explore different transfection methods and optimize conditions. Efficient transfection is essential for successful gene transposition.

3. How can I verify the transposition activity of the piggyBac Transposon System Kit?

A: The transposon plasmid in this kit contains the CopGFP gene. Successfully transposed cells will exhibit green fluorescence under a fluorescence microscope. Due to cell heterogeneity, transfection and transposition efficiencies may vary across cell types. To minimize transposition variability, optimize transfection methods for target cells.

4. Can cells constructed with the piggyBac Transposon System Kit be stably passaged?

A: Yes. The piggyBac Transposon System Kit targets genomic DNA for gene transposition, allowing the genotype of target cells to be stably inherited. Note: Maintain transposed cells with half-dose puromycin for stability.



1. Project Information

Cell Name	MC38
Gene	Cas9

2. Detection of Transposition Results

MC38 cells were selected with puromycin for 2 weeks, resulting in MC38-PB-Cas9 transposed cells. The sgRNA targeting ITGA5 demonstrated a knockout efficiency of up to 95%, confirming high-activity Cas9 protein expression post-transposition in MC38 cells.



Figure 2. Sanger Sequencing Results of ITGA5 Gene Knockout in MC38-PB-Cas9 Cells

🐼 editgene | EDITGENE Co., Ltd.

Contributions				Indel Distribution			Traces	
Status ⑦		Guide Target	0		PAM Sequences ⑦	Indel %	Model Fit (R²) 🗇	Knockout-Score ⑦
Succeeded		I TCA GAC	AGCT	GCGGACAGCTGAT GATGGGAGACCTC	d GGG ≥ AGG	95	0.95	88
FLATIVE CONTRIBUT		CH SEQUENC		AI IZED)				nowfath by \$SYNTHEGO
	IND			SEQUENCE				
	F1 +1	+1	4196	ACCCCTECTCATEGAGCGGACAGC		COTOCOCACOOTOTA	CATCTATCTOCAGCOCC	
	2 -1	-1 -	1996	ACCCCTGCTCATGGAGCGGACAGC	GATEGGAGAC - TCAGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	-2	-2 .	696	ACCCCTGCTCATGGAGCGGACAG-	GATEGGAGAC CTCAGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
+		0 -	5%	ACCCCTGCTCATGGAGCGGACAGC	GATEGGAGAC CTCAGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	12 +1	+1 .	496	ACCCCTGCTCATGGAGCGGACAGC	GATEGEAGAC NCTCAGEA	GGTGGGCAGGGTCTA	CATCTATCTGCAGCGCC	
0	-10	-10 ,	3%	ACCCCTGCTCATGGAGCGGACAGC	GATGGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	-10	-10	3%	ACCCCTGCTCATGGAGCGGACAGC	GATEGEAGA-	-TGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	2 -4	-4 .	3%	ACCCCTGCTCATGGAGCGGACAGC	GATEGEAGA AGEAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	2-1	-1 .	396	ACCCCTGCTCATGGAGCGGACAGC	TCATGGAGCGGACAGCT GATGGGAGA- CTCAGGAGGTGGGCAGGGTCTACATCTATCTGCAGCGCCC			
	P -6	-6 •	296	ACCCCTGCTCATGGAGCGGACAGC	TCATGGAGCGGACAGCT GATGGGA AGGAGGTGGGCAGGGTCTACATCTATCTGCAGCGCCC			
	2 -5	-5 .	296	ACCCCTGCTCATGGAGCGGACAGC	GATGGGAGAGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
fragment de	faction -17	-17 -	296	ACCCCTGCTCATGGAGCGGACAGC	NT	- GTGGGCAGGGTCTA	CATCTATCTGCAGCGCC	
	12 -7	-7 (196	ACCCCTGCTCATGGAGCGGACAGC	GATGGCAGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	1 2 -12	-12	196	ACCCCTGCTCATGGAGCGGACAGC	GATGGGA	-TGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	P -3	-3 (196	ACCCCTGCTCATGGAGCGGACAGC	GATEGEAGA CAGEAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	F ² -3	-3 ,	196	ACCCCTGCTCATGGAGCGGACAGC	GATEGGAGAC AGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	
	1 -3	-3 (196	ACCCCTGCTCATGGAGCGGACA	GATGGGAGAC CTCAGGAG	GTGGGCAGGGTCTAC	ATCTATCTGCAGCGCCC	

Figure 3. ICE Analysis of ITGA5 Gene Knockout Efficiency in MC38-PB-Cas9 Cells

Notes

- 1. This product is intended for research use only in laboratory settings. Please comply with relevant laws, regulations, and ethical guidelines; any consequences from improper use are the sole responsibility of the user.
- Follow the recommended guidelines for transportation, storage, and use of reagents. Avoid repeated freeze-thaw cycles unless necessary. The company is not responsible for experimental failures resulting from improper storage or handling.



• Appendix					
EDITGENE provides the following transposon plasmids:					
Plasmid Name	Description				
DD CMV MCS EE1a ConCED T24 Duro	Dual promoter transposon vector,				
rb-cmv-mcs-Eria-coporr-12A-ruio	CopGFP, Puromycin				
DD CAC MCS EE1g ConCED T2A Duno	Dual promoter transposon vector,				
rb-CAO-MCS-Er1a-Coporr-12A-ruio	CopGFP, Puromycin				
PB-CMV-MCS-T2A-Puro	Single promoter transposon vector, Puromycin				
PB-EF1α-MCS-T2A-Puro	Single promoter transposon vector, Puromycin				
PB-CAG-MCS-T2A-Puro	Single promoter transposon vector, Puromycin				
	AppendixEDITGENE provides the following transpPlasmid NamePB-CMV-MCS-EF1α-CopGFP-T2A-PuroPB-CAG-MCS-EF1α-CopGFP-T2A-PuroPB-CAG-MCS-T2A-PuroPB-EF1α-MCS-T2A-PuroPB-CAG-MCS-T2A-PuroPB-CAG-MCS-T2A-Puro				

